Abstract
Objective: To investigate the inhibitory activity of HIF-1 by triptolide and manasaantin A, two cell-based models with luciferase report gene assay were established. Method: Two cell-based models of HIF-1 were used to evaluate HIF-1 inhibition activity of triptolide and manasaantin A. Secreted VEGF expression induced by hypoxia was detected by ELISA with two compounds. The growth inhibition of different solid tumor cell lines was measured by the MTT assay. Result: The expression of firefly luciferase was induced by hypoxia in U251-HRE and T47D-HRE cells. U251-HRE model was suitable for the detection of HIF-1 inhibition activity of triptolide. The IC50 of triptolide on HIF-1 activity was (3.4 ± 0.5) × 10-8 mol·L -1. The report gene assay using T47D cells co-transfected with pGL2-TK-HRE and pRL-CMV showed more sensitive inhibition activity of HIF-1 on manassantin A than that of detected by U251-HRE model. The IC50 of manassantin A on HIF-1 activity was (2.4 ±0.6) × 10-8 mol·L-1. HIF-1 target gene VEGF was also inhibited by test compounds on protein level in T47D cells. Manasaantin A showed selective inhibition on the growth of human solid cancer cell lines, especially on breast cancer and pancreatic cancer cells. Meanwhile, triplotide showed strong proliferation inhibition activity on all tested cell lines. Conclusion: It is very important to select a suitable cell-based report gene assay of HIF-1 for screening of different kinds of inhibitor.
Original language | English (US) |
---|---|
Pages (from-to) | 2151-2155 |
Number of pages | 5 |
Journal | Zhongguo Zhongyao Zazhi |
Volume | 37 |
Issue number | 14 |
DOIs | |
State | Published - Jul 15 2012 |
Externally published | Yes |
Keywords
- Hypoxia-induciblefactor 1
- Inhibitor
- Manassantin A
- Screening model
- Triptolide
- Tumor
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)
- Complementary and alternative medicine
- Pharmacology (medical)